Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LUCD
Strong SellSinkerLucid Diagnostics Inc. · Healthcare · United States · $189M · Avg Vol: $776K/d
COMPANY DESCRIPTION
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company dedicated to the early detection of esophageal precancer and cancer through its proprietary EsoGuard® Esophageal DNA Test and EsoCheck® device. The company’s competitive advantage lies in offering a minimally invasive, first-in-class solution that addresses a significant unmet medical need for timely intervention in esophageal adenocarcinoma.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.5M | 0.4M | 2.4M | 4.3M | 4.7M | 75.2% | 5.4M | 6.3M | — | 33.9% |
| EPS | -1.51 | -0.33 | -0.28 | -0.35 | -0.43 | — | -0.41 | -0.24 | -0.17 | — |
| Shares | 34.9M | 190.8M | 190.8M | 190.8M | 131.1M | +275.4% | — | — | — | — |
| Debt | 0 | 2.0M | 15.3M | 21.3M | 25.8M | 134.6% | 24.9M | — | — | — |
| Equity | 54.7M | 23.0M | -2.3M | 5.4M | 10.9M | -33.1% | — | — | — | — |
| Op CF | -17.7M | -29.7M | -32.8M | -44.1M | -46.5M | — | -46.9M | — | — | — |
| Inv CF | -0.9M | -4.1M | -0.2M | -0.6M | -0.2M | — | — | — | — | — |
| Fin CF | 72.1M | 2.6M | 29.5M | 48.2M | 59.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LUCD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LUCD | Lucid Diagnostics Inc.(you) | $189M | 4 | Strong Sell |
| EBR.AX | EBR Systems, Inc. | $148M | 5 | Strong Sell |
| PAIN.V | Vector Science and Therapeutics Corp. | $233M | 8 | Strong Sell |
| QSI | Quantum-Si incorporated | $171M | 11 | Strong Sell |
| MBOT | Microbot Medical Inc. | $99M | 7 | Strong Sell |
| OWLT | Owlet, Inc. | $146M | 15 | Strong Sell |
| QTRX | Quanterix Corporation | $125M | 14 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 13 | Strong Sell |
| RPID | Rapid Micro Biosystems, Inc. | $79M | 6 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%